ORAL ABSTRACT SESSIONS FRIDAY 28 OC<strong>TO</strong>BER 2016 15.55 [OA-425-28] The effect of risk factor control on tuberculosis in Taiwan: a modelling study C-H Wang, H-H Lin (Taiwan) 16.05 [OA-426-28] Challenges in diagnosing diabetes among those with newly diagnosed pulmonary TB: diagnostic variability according to diabetes disease severity D Grint, A Riza, C Ugarte-Gil, K Ronacher, B Alisjahbana, H Dockrell, R van Crevel, J Critchley, on behalf of the TANDEM Consortium (United Kingdom, Romania, Peru, South Africa, Indonesia, Netherlands) 16.15 [OA-427-28] A rapid assessment of the nutritional status of TB patients and the integration of a nutrition assistance programme in Ethiopia J Ahmed, A Kassa, M H/silassie, A Fantaye (Ethiopia) 16.25 [OA-428-28] Alcohol and substance use among participants in a clinical trial receiving home-based DOT for tuberculosis C Pinedo, J Jimenez, K Tintaya, S R Leon, J M Coit, M B Milstein, L Lecca, C D Mitnick (Peru, United States of America) ORAL ABSTRACT SESSION 19 3 15:15-16:45 3 SESSION ROOM 12 DRUGS FOR MRD-TB: CHALLENGES AND SUCCESSES Co-chairs: Francesca Conradie (South Africa), ID Rusen (Canada) – Section: Tuberculosis 15.15 [OA-429-28] Timing of acquired resistance to fluoroquinolones and second-line injectable drugs during treatment of MDR-TB P Cegielski, C Contreras, T Dalton, V Leimane, K Kliiman, H J Kim, M van der Walt, T Tupasi, O Demikhova, L Via, C Kvasnovsky, L Diem, M Yagui, J Bayona, Preserving Effective TB Treatment Study (PETTS) (United States of America, Peru, Latvia, Estonia, Korea, Republic of, South Africa, Philippines, Russian Federation) 15.25 [OA-430-28] Comparable 12-month incidence of renal insufficiency in MDR-TB patients treated with standard kanamycin-based regimens or concomitantly with tenofovir in Namibia E Sagwa, N Ruswa, F Mavhunga, T Rennie, A Mengistu, A K Mantel-Teeuwisse (Netherlands, Namibia) 15.35 [OA-431-28] Dose-ranging activity of clofazimine in combination with the first-line regimen in the mouse model of tuberculosis treatment N Ammerman, R Swanson, E Bautista, H Guo, D Almeida, E Nuermberger, J Grosset (United States of America, South Africa) 15.45 [OA-432-28] Roll-out of new drugs to treat DR-TB: success and challenges with implementation N Misra, I Master (South Africa) 15.55 [OA-433-28] Treatment outcome in patients with multidrug-resistant tuberculosis as measured by sputum culture conversion rate in Rwanda M C Muvunyi, J C S Ngabonziza, Y Mucyo, G Mutembayire, P Migambi, M Gasana (Rwanda) 16.05 [OA-434-28] Predictors of unfavourable treatment outcome in adults with multidrug-resistant tuberculosis in India D Nair, B Velayutham, K Thiruvengadam, J P Tripathy, A D Harries, K S Sachdeva, M Natrajan, S Swaminathan (India, France) 16.15 [OA-435-28] DR-TB treatment costs: trends towards more affordability under threat with new drugs C Perrin, W Bellamy, G Brigden, S Cloez (France, United States of America, Switzerland) 16.25 [OA-436-28] High rates of ocular toxicity associated with ethambutol in the treatment of multidrug-resistant tuberculosis in South Africa K N Nelson, N R Gandhi, N S Shah, S Allana, A Campbell, K Mlisana, J C M Brust (United States of America, South Africa) 126 CONFRONTING RESISTANCE: FUNDAMENTALS <strong>TO</strong> INNOVATION - THE 47 TH UNION WORLD CONFERENCE ON LUNG HEALTH
FRIDAY 28 OC<strong>TO</strong>BER 2016 ORAL ABSTRACT SESSIONS ORAL ABSTRACT SESSION 20 3 15:15-16:45 3 SESSION ROOM 11A TB INFECTION CONTROL: <strong>TO</strong>O FAST, <strong>TO</strong>O SLOW OR JUST RIGHT? Co-chairs: Carrie Tudor (Switzerland), Enos Masini (Kenya) – Section: Tuberculosis 15.15 [OA-437-28] Shortening time to diagnosis and treatment initiation for infectious TB and drug-resistant TB cases by implementation of FAST in Viet Nam H Le, N V Nguyen, P N Tran (Viet Nam) 15.25 [OA-438-28] FAST: a new strategy for TB infection control S Sultana, P Daru (Bangladesh) 15.35 [OA-439-28] Comparison of indoor contacts in Zambia and South Africa suggests infection control intervention targeting should be informed by local data N McCreesh, C Looker, P J Dodd, I D Plumb, K Shanaube, E L Corbett, H Ayles, R G White (United Kingdom, Zambia, Malawi) 15.45 [OA-440-28] TB infection control assessment at high-burden antiretroviral therapy centres under the ´3Is´ project in India: country experience R Deshmukh, R S Gupta, B B Rewari, S A Nair, R Ramchandran, M Parmar, S Nicole, P Harvey (India) 15.55 [OA-441-28] Infection control in MDR decentralised sites in South Africa: a baseline study A Peters, M Mahlepe, Z Claassen, J Peters, N Ndjeka, F Peters, I Asia (South Africa, United Kingdom) 16.05 [OA-442-28] Exploring level of knowledge of health care staff on TB infection control measures in Afghanistan A Momand, G Qader, M K Rashidi, D Safi, H Momand, N Ahmadzada, P Suariz, A Hamim (Afghanistan, United States of America) 16.15 [OA-443-28] Assessing tuberculosis patients’ knowledge, attitudes and practices: research to strengthen infection control interventions in PHC facilities in South Africa N G Kigozi, M C Engelbrecht, A Janse van Rensburg, H C Janse van Rensburg, J C Heunis (South Africa) 16.25 [OA-444-28] Incidence of tuberculosis among health workers at public health care facilities in two regions of Ethiopia A Ayalew, D Habte, N Hiruy, G Gizatie, B Reshu, L Fekadu, D Jerene, P Suarez (Ethiopia, United States of America) FRIDAY 28 OCT 26-29 OC<strong>TO</strong>BER 2016 - LIVERPOOL - UNITED KINGDOM 127
Change language